The Viewpoint titled “Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability,” published in the May 3, 2022, issue of JAMA, misreported that the Health Resources and Services Administration (HRSA) sued 6 pharmaceutical manufacturers when the agency had instead issued enforcement letters. The Viewpoint also should have used the words interpretive guidance instead of the word rules when talking about the history of court rulings on compliance with the HRSA interpretive guidance. This article has been corrected online.